NZ335317A - A proanthocyanidin polymer anti-diarrheal composition formulated as a suppository or as an oral formulation which is protected from stomach acid action - Google Patents

A proanthocyanidin polymer anti-diarrheal composition formulated as a suppository or as an oral formulation which is protected from stomach acid action

Info

Publication number
NZ335317A
NZ335317A NZ335317A NZ33531797A NZ335317A NZ 335317 A NZ335317 A NZ 335317A NZ 335317 A NZ335317 A NZ 335317A NZ 33531797 A NZ33531797 A NZ 33531797A NZ 335317 A NZ335317 A NZ 335317A
Authority
NZ
New Zealand
Prior art keywords
spp
polymer composition
proanthocyanidin polymer
diarrhea
composition
Prior art date
Application number
NZ335317A
Other languages
English (en)
Inventor
Edward J Rozhon
Atul S Khandwala
Akram Sabouni
Original Assignee
Shaman Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shaman Pharmaceuticals Inc filed Critical Shaman Pharmaceuticals Inc
Publication of NZ335317A publication Critical patent/NZ335317A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NZ335317A 1996-10-16 1997-10-14 A proanthocyanidin polymer anti-diarrheal composition formulated as a suppository or as an oral formulation which is protected from stomach acid action NZ335317A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73077296A 1996-10-16 1996-10-16
PCT/US1997/018845 WO1998016111A1 (en) 1996-10-16 1997-10-14 Enteric formulations of proanthocyanidin polymer antidiarrheal compositions

Publications (1)

Publication Number Publication Date
NZ335317A true NZ335317A (en) 2001-02-23

Family

ID=24936755

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ335317A NZ335317A (en) 1996-10-16 1997-10-14 A proanthocyanidin polymer anti-diarrheal composition formulated as a suppository or as an oral formulation which is protected from stomach acid action

Country Status (14)

Country Link
US (5) US7341744B1 (enExample)
EP (3) EP0935417B1 (enExample)
JP (1) JP4195728B2 (enExample)
KR (1) KR100467532B1 (enExample)
AT (1) ATE430477T1 (enExample)
AU (1) AU4988197A (enExample)
CA (1) CA2269078C (enExample)
DE (1) DE69739394D1 (enExample)
DK (1) DK0935417T3 (enExample)
ES (1) ES2326933T3 (enExample)
NZ (1) NZ335317A (enExample)
PT (1) PT935417E (enExample)
TW (1) TW537898B (enExample)
WO (1) WO1998016111A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739394D1 (de) * 1996-10-16 2009-06-18 Napo Pharmaceuticals Inc Enteral-formulierungen von proanthocyanidzusammensetzungen gegen diarrhöe
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
CA2363454A1 (en) * 1999-02-15 2000-08-17 The Nikka Whisky Distilling Co., Ltd. Use of proanthocyanidin
PT1178778E (pt) * 1999-05-17 2006-06-30 D B F Granulos que contem uma substancia vegetal e o seu procedimento de preparacao
NZ528883A (en) * 2001-03-28 2005-12-23 Asahi Breweries Ltd Proteotoxin neutralizer
CO5400144A1 (es) * 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
GB0321996D0 (en) * 2003-09-19 2003-10-22 Novartis Nutrition Ag Organic compounds
CA2541578C (en) 2003-10-10 2014-03-25 Ethypharm Sustained-release microgranules containing gingko biloba extract and the process for manufacturing these
KR100720817B1 (ko) * 2003-12-26 2007-05-21 (주)아모레퍼시픽 식물 추출물을 함유하는 제제 및 그 제조방법
JP2006232752A (ja) * 2005-02-25 2006-09-07 Tokyo Univ Of Marine Science & Technology コレステロール及び中性脂肪吸収抑制剤及びこれを含む食品
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US20090076132A1 (en) * 2005-03-11 2009-03-19 Gary Pekoe Antiviral compositions and methods of treatment
JP5167461B2 (ja) * 2005-09-16 2013-03-21 国立医薬品食品衛生研究所長 炎症性腸疾患予防剤
US7351853B2 (en) * 2006-01-23 2008-04-01 Albion Advanced Nutrition Method of manufacturing a granular mineral composition
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
ES2660551T3 (es) * 2006-05-01 2018-03-22 Napo Pharmaceuticals, Inc. Composiciones y métodos para tratar o prevenir cáncer de colon
DK2241318T3 (da) 2006-05-01 2013-01-21 Napo Pharmaceuticals Inc Fremgangsmåde til behandling af irritabelt tyktarmssyndrom med fremherskende forstoppelse
US8048413B2 (en) * 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
CN101102783B (zh) * 2006-12-13 2010-11-17 北京绿色金可生物技术股份有限公司 黑大豆皮提取物及其提取方法和应用
WO2008115605A1 (en) * 2007-03-22 2008-09-25 Ibix Clear bismuth treatments and methods for making
EP2155251B1 (en) * 2007-05-08 2013-09-25 Rq Bioscience, Inc. Therapeutic compositions and methods for treating gram-negative bacterial infections
US8734867B2 (en) * 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
EP2252601B1 (en) * 2008-01-24 2012-12-19 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2010033626A1 (en) * 2008-09-19 2010-03-25 Institute For Oneworld Health Compounds, compositions and methods comprising imidazole and triazole derivatives
US20100034968A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Polymer coating process using dry glidant in a rotor processor
US8807070B2 (en) * 2008-08-07 2014-08-19 Vector Corporation Rotor processor for dry powders
US20100034967A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Dry polymer layering using a rotor processor
FR2938430B1 (fr) * 2008-11-14 2011-05-20 Debregeas Et Associes Pharma Granules a base de plantes
PL2403938T3 (pl) * 2009-03-04 2020-09-21 Liveleaf, Inc. Sposób i materiał do miejscowo aktywowanego kompleksowania cząsteczek biologicznych
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EA023814B1 (ru) * 2009-08-26 2016-07-29 Гленмарк Фармасьютикалс Лтд. Способ получения полимерных композиций на основе проантоцианидина для фармацевтических форм
US8652534B2 (en) 2009-10-14 2014-02-18 Berry Pharmaceuticals, LLC Compositions and methods for treatment of mammalian skin
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
BR112013010774A2 (pt) * 2010-10-31 2017-03-21 Napo Pharmaceuticals Inc "usos de crofelemer no tratamento de diarreia associada ao hiv"
WO2012101008A1 (en) 2011-01-27 2012-08-02 Glenmark Pharmaceuticals Limited Process for the production of proanthocyanidin polymeric composition
US9895341B2 (en) 2011-04-01 2018-02-20 Ocean Spray Cranberries, Inc. Inflammation and immunity treatments
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CA2866260A1 (en) * 2012-03-13 2013-09-19 Piramal Enterprises Limited Herbal composition for the treatment of metabolic disorders
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms
ITMI20130476A1 (it) * 2013-03-28 2014-09-29 Novintethical Pharma Sagl Composizioni per il trattamento di disturbi gastro-intestinali a base di complessi di tannini con proteine
CN103536583B (zh) * 2013-11-01 2015-02-25 潍坊医学院 一种原花青素缓释纳米微球及制备方法和应用
ES2742106T3 (es) 2014-05-12 2020-02-13 Alfasigma Spa Nueva forma de cristal solvatado de rifaximina, producción, composiciones y usos de la misma
WO2015184101A1 (en) * 2014-05-29 2015-12-03 Jaguar Animal Health, Inc. Methods of treating diarrhea in neonatal and young non-human animals
WO2015184109A1 (en) * 2014-05-29 2015-12-03 Jaguar Animal Health, Inc. Methods of treating diarrhea in adult non-human animals
US20170095442A1 (en) * 2014-05-29 2017-04-06 Jaguar Animal Health, Inc. Methods of Treating Salmonella-Induced Diarrhea in Non-Human Animals
WO2016112312A1 (en) * 2015-01-09 2016-07-14 Jaguar Animal Health Methods of treating diarrhea in companion animals
WO2016138125A1 (en) * 2015-02-26 2016-09-01 Jaguar Animal Health, Inc. Methods of treating diarrhea and promoting intestinal health in non-human animals
US20180021297A1 (en) * 2015-02-26 2018-01-25 Jaguar Health, Inc. Use Of Croton- Or Calophyllum-Derived Proanthocyanidin Polymers Or Botanical Extracts In Combination With Rifaximin For The Treatment Of Diarrhea In Non-Human Animals
WO2018022475A1 (en) * 2016-07-25 2018-02-01 Jaguar Health, Inc Methods of treating porcine epidemic diarrheal virus in piglets
IT201600122310A1 (it) 2016-12-01 2018-06-01 Sofar Spa Composizione per uso nella terapia di alterazioni dell'intestino
BR112018076609B1 (pt) 2016-12-15 2023-02-14 Société des Produits Nestlé S.A. Composição alimentícia para animais de estimação, seus usos, e métodos não terapêutico para modular a quantidade e para medição de uma alteração na quantidade de pelo menos uma dentre bifidobacterium, lactobacillus ou clostridium perfringens
JOP20190275A1 (ar) * 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
US20210361698A1 (en) * 2017-12-27 2021-11-25 Suntory Holdings Limited Composition for improving intestinal barrier function
KR20200008826A (ko) 2018-07-17 2020-01-29 성균관대학교산학협력단 대장균을 이용한 단백질가수분해효소 k의 생산 방법
CN109464491B (zh) * 2018-12-03 2022-02-01 四川省畜牧科学研究院 诃子组合物及其在制备预防和/或治疗腹泻和/或乳房炎的产品中的应用
WO2022115481A1 (en) * 2020-11-24 2022-06-02 Napo Pharmaceuticals, Inc. Methods and compositions for treating post-acute infection gastrointestinal disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377201A1 (fr) * 1977-01-18 1978-08-11 Fabre Sa Pierre Composition pharmaceutique a activite anti-inflammatoire et vasculotrope
SE446940B (sv) * 1983-02-16 1986-10-20 Carl Axel Virdalm Medel for bekempande av sjukdomstillstand i matsmeltningsapparaten innehallande skal eller ytterdelar av ber eller frukter
US4698360B1 (en) * 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
EP0214317B1 (fr) * 1985-08-30 1988-08-17 Societe Des Produits Nestle S.A. Produit diététique à activité dépurative et anti-diarrhéique et son procédé de préparation
US5141735A (en) * 1990-06-18 1992-08-25 Hoffman-La Roche, Inc. Substituted amino-benzodiazepines having anitviral activity
US5211944A (en) * 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
SI9011933A (sl) 1990-10-15 1998-06-30 TANIN SEVNICA Kemična industrija p.o. Kostanjev taninski ekstrakt, postopek za njegovo pridobivanje in njegova uporaba
US5234922A (en) 1992-09-28 1993-08-10 University Of Iowa Research Foundation Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea
US5750496A (en) * 1996-08-12 1998-05-12 Utah State University Method of controlling cryptosporidium infectons using protease inhibitors
DE69739394D1 (de) 1996-10-16 2009-06-18 Napo Pharmaceuticals Inc Enteral-formulierungen von proanthocyanidzusammensetzungen gegen diarrhöe

Also Published As

Publication number Publication date
EP2255661A2 (en) 2010-12-01
EP2255661A3 (en) 2010-12-22
EP2060183A2 (en) 2009-05-20
EP2060183A3 (en) 2009-06-03
DK0935417T3 (da) 2009-08-10
US7341744B1 (en) 2008-03-11
US8574634B2 (en) 2013-11-05
CA2269078C (en) 2012-01-24
ES2326933T3 (es) 2009-10-21
DE69739394D1 (de) 2009-06-18
AU4988197A (en) 1998-05-11
US20050019389A1 (en) 2005-01-27
KR20000049206A (ko) 2000-07-25
EP0935417B1 (en) 2009-05-06
US7323195B2 (en) 2008-01-29
PT935417E (pt) 2009-07-17
US20140329896A1 (en) 2014-11-06
JP4195728B2 (ja) 2008-12-10
US20140011869A1 (en) 2014-01-09
EP0935417A4 (en) 2006-08-30
JP2001524938A (ja) 2001-12-04
ATE430477T1 (de) 2009-05-15
EP0935417A1 (en) 1999-08-18
KR100467532B1 (ko) 2005-01-24
US20090148397A1 (en) 2009-06-11
TW537898B (en) 2003-06-21
CA2269078A1 (en) 1998-04-23
WO1998016111A1 (en) 1998-04-23

Similar Documents

Publication Publication Date Title
CA2269078C (en) Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
EP2061327B1 (en) Compositions for treating or preventing inflammatory bowel disease
US7556831B2 (en) Method for treatment of constipation-predominant irritable bowel syndrome
AU775330B2 (en) Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
HK1130158A (en) Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
HK1151189A (en) Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
AU2013201685B2 (en) Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
MXPA99003517A (en) Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
HK1131002B (en) Compositions for treating or preventing inflammatory bowel disease
HK1178383A (en) Compositions and methods for treating or preventing colon cancer
HK1178383B (en) Compositions and methods for treating or preventing colon cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: PS PHARMACEUTICALS INC, US

Free format text: OLD OWNER(S): SHAMAN PHARMACEUTICALS, INC.

RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired